Savara at a Glance
Savara is an orphan lung disease company and our pipeline is comprised of the following inhaled investigational therapies: Molgradex, Apulmiq, and AeroVanc.
MOLGRADEX (inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF) is being evaluated for autoimmune pulmonary alveolar proteinosis (aPAP).
APULMIQ (inhaled ciprofloxacin) will be evaluated for the treatment of non-cystic fibrosis bronchiectasis (NCFB).
AEROVANC (vancomycin hydrochloride inhalation powder) is being evaluated for the treatment of persistent methicillin-resistant Staphylococcus aureus, or MRSA, lung infection in CF.
Savara’s strategy involves broadening its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field.